(ABC) transporters (particularly ABCB1), resulting in a variety of structurally and pharmacologically unrelated drugs efflux. The multidrug resistance (MDR) phenomenon could be reversed by ABCB1 inhibitors. Now, JL-A7 as the lead compound based on a triazol-N-ethyl-tetrahydroisoquinoline scaffold, 18 compounds were designed and synthesized. Substitution in para positions yielded high activities toward
癌症
化学疗法失败通常是由于
ATP结合盒(ABC)转运蛋白(尤其是ABCB1)的过表达,导致各种与结构和药理无关的药物外排。ABCB1
抑制剂可以逆转多药耐药性(MDR)现象。现在,以三唑-N-乙基-
四氢异喹啉骨架为基础的JL-A7作为先导化合物,设计合成了18种化合物。对位取代产生了对ABCB1的高活性。此外,化合物5可以有效地阻断ABCB1的药物外流功能并增加抗癌药物的积累,从而在MDR细胞中达到有效的治疗浓度。